Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the therapeutic effectiveness of such neutralizing antibodies, F...

Descripción completa

Detalles Bibliográficos
Autores principales: Dippel, Andrew, Gallegos, Austin, Aleti, Vineela, Barnes, Arnita, Chen, Xiaoru, Christian, Elizabeth, Delmar, Jared, Du, Qun, Esfandiary, Reza, Farmer, Erika, Garcia, Andrew, Li, Qing, Lin, Jia, Liu, Weiyi, Machiesky, LeeAnn, Mody, Neil, Parupudi, Arun, Prophet, Meagan, Rickert, Keith, Rosenthal, Kim, Ren, Song, Shandilya, Harini, Varkey, Reena, Wons, Kevin, Wu, Yuling, Loo, Yueh-Ming, Esser, Mark T., Kallewaard, Nicole L., Rajan, Sarav, Damschroder, Melissa, Xu, Weichen, Kaplan, Gilad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733695/
https://www.ncbi.nlm.nih.gov/pubmed/36476037
http://dx.doi.org/10.1080/19420862.2022.2152526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733695/
https://www.ncbi.nlm.nih.gov/pubmed/36476037
http://dx.doi.org/10.1080/19420862.2022.2152526

Ejemplares similares